Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
85% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. QLTI: No Debt )
QLTI' s 10-Year Cash to Debt Range
Min: 0.7   Max: No Debt
Current: No Debt

Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
89% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. QLTI: No Debt )
QLTI' s 10-Year Interest Coverage Range
Min: 24.57   Max: 9999.99
Current: No Debt

24.57
9999.99
F-Score: 2
Z-Score: 14.61
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -17.51
QLTI's ROE (%) is ranked higher than
75% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. QLTI: -17.51 )
QLTI' s 10-Year ROE (%) Range
Min: -53.3   Max: 51.44
Current: -17.51

-53.3
51.44
ROA (%) -16.80
QLTI's ROA (%) is ranked higher than
74% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. QLTI: -16.80 )
QLTI' s 10-Year ROA (%) Range
Min: -48.69   Max: 28.57
Current: -16.8

-48.69
28.57
ROC (Joel Greenblatt) (%) -102.05
QLTI's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. QLTI: -102.05 )
QLTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1043.82   Max: 55.56
Current: -102.05

-1043.82
55.56
EBITDA Growth (%) 7.10
QLTI's EBITDA Growth (%) is ranked higher than
85% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. QLTI: 7.10 )
QLTI' s 10-Year EBITDA Growth (%) Range
Min: -34.9   Max: 84.4
Current: 7.1

-34.9
84.4
EPS Growth (%) 46.10
QLTI's EPS Growth (%) is ranked higher than
97% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. QLTI: 46.10 )
QLTI' s 10-Year EPS Growth (%) Range
Min: -66.5   Max: 103.8
Current: 46.1

-66.5
103.8
» QLTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

QLTI Guru Trades in Q3 2013

Jim Simons 93,664 sh (-21%)
» More
Q4 2013

QLTI Guru Trades in Q4 2013

Jim Simons 115,164 sh (+22.95%)
» More
Q1 2014

QLTI Guru Trades in Q1 2014

Jim Simons 95,164 sh (-17.37%)
» More
Q2 2014

QLTI Guru Trades in Q2 2014

Jim Simons 52,364 sh (-44.97%)
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2011-09-30 Sold Out 0.004%$5.65 - $7.57 $ 4.02-42%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.49
QLTI's P/B is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. QLTI: 1.49 )
QLTI' s 10-Year P/B Range
Min: 0.28   Max: 4.48
Current: 1.49

0.28
4.48
EV-to-EBIT -2.51
QLTI's EV-to-EBIT is ranked higher than
71% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: -2.51 )
QLTI' s 10-Year EV-to-EBIT Range
Min: -13.3   Max: 38.1
Current: -2.51

-13.3
38.1
Shiller P/E 7.04
QLTI's Shiller P/E is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: 7.04 )
QLTI' s 10-Year Shiller P/E Range
Min: 33.73   Max: 524.5
Current: 7.04

33.73
524.5
Current Ratio 29.28
QLTI's Current Ratio is ranked higher than
98% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. QLTI: 29.28 )
QLTI' s 10-Year Current Ratio Range
Min: 1.1   Max: 85.25
Current: 29.28

1.1
85.25
Quick Ratio 29.28
QLTI's Quick Ratio is ranked higher than
98% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. QLTI: 29.28 )
QLTI' s 10-Year Quick Ratio Range
Min: 1.07   Max: 85.25
Current: 29.28

1.07
85.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.62
QLTI's Price/Net Cash is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. QLTI: 1.62 )
QLTI' s 10-Year Price/Net Cash Range
Min: 1.07   Max: 87
Current: 1.62

1.07
87
Price/Net Current Asset Value 1.54
QLTI's Price/Net Current Asset Value is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. QLTI: 1.54 )
QLTI' s 10-Year Price/Net Current Asset Value Range
Min: 0.86   Max: 443.75
Current: 1.54

0.86
443.75
Price/Tangible Book 1.49
QLTI's Price/Tangible Book is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. QLTI: 1.49 )
QLTI' s 10-Year Price/Tangible Book Range
Min: 0.38   Max: 24.31
Current: 1.49

0.38
24.31
Price/DCF (Projected) 2.46
QLTI's Price/DCF (Projected) is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: 2.46 )
QLTI' s 10-Year Price/DCF (Projected) Range
Min: 0.28   Max: 200
Current: 2.46

0.28
200
Earnings Yield (Greenblatt) -39.80
QLTI's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. QLTI: -39.80 )
QLTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.6   Max: 1966.4
Current: -39.8

2.6
1966.4
Forward Rate of Return (Yacktman) -0.56
QLTI's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. QLTI: -0.56 )
QLTI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.4   Max: 18.4
Current: -0.56

-1.4
18.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QLT.Canada, QLT.Germany
QLT, Inc., was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company is developing its synthetic retinoid program for the treatment of certain inherited retinal diseases. Its competitors include major pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.
» More Articles for NAS:QLTI

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012 
QLT Inc. Reports Operating Results (10-K) Mar 01 2011 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 3,000 Shares Nov 08 2010 
QLT Inc. Reports Operating Results (10-Q) Nov 03 2010 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 5,000 Shares Jun 23 2010 
QLT Inc. (QLTI) CFO Cameron Nelson buys 10,000 Shares Nov 10 2009 
QLT Inc. Reports Operating Results (10-Q) Nov 06 2009 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 10,000 Shares Nov 04 2009 
QLT Inc. Reports Operating Results (10-Q) Aug 06 2009 
QLT Announces Second Quarter Results for 2009 Jul 28 2009 

More From Other Websites
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer Oct 24 2014
7:01 am QLT Inc appoints Geoffrey Cox as Interim Chief Executive Officer Oct 24 2014
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer Oct 24 2014
Endo Buyout Of Auxilium Joins Two Changing Firms Oct 09 2014
QLT INC/BC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events,... Oct 09 2014
QLT Announces Merger With Auxilium Pharmaceuticals, Inc. Terminates for Superior Proposal Oct 09 2014
Auxilium Pharmaceuticals Favors QLT Deal Over Endo Bid Sep 23 2014
Auxilium Says Endo Takeover Offer Undervalues Company Sep 22 2014
[$$] Auxilium Sticks With QLT's Merger Deal Sep 22 2014
Auxilium Pharma rejects Endo's takeover offer Sep 22 2014
Auxilium Pharma rejects Endo's takeover offer Sep 22 2014
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 22 2014
QLT Provides Further Update on Merger With Auxilium Pharmaceuticals, Inc. Sep 22 2014
Auxilium Mulls Endo Bid; Is $2.2 Billion Enough? Sep 17 2014
Auxilium Mulls Endo Bid; Street Eyes A Higher Price Sep 17 2014
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 17 2014
QLT Provides Update on Merger With Auxilium Pharmaceuticals, Inc. Sep 17 2014
QLT Unveils Positive Retreatment Study Data Sep 15 2014
QLT Inc. (QLTI) is Overbought: Is A Drop Coming? Sep 12 2014
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK